Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data Since previewing the feature in May, more ...
No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. We conducted a phase 3, ...
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results